AURA Quote, Financials, Valuation and Earnings

NovaBay Pharmaceuticals has a net margin of -- compared to Aura Biosciences's net margin of -49.65%. Aura Biosciences's return on equity of -- beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Aura Biosciences has a consensus price target of $21.50, signalling upside risk potential of 235.94%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 22.83%. Given that Aura Biosciences has higher upside potential than NovaBay Pharmaceuticals, analysts believe Aura Biosciences is more attractive than NovaBay Pharmaceuticals.

Aura Biosciences has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.443, suggesting its less volatile than the S&P 500 by 55.681%.

Aura Biosciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Aura Biosciences pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Aura Biosciences quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Aura Biosciences's net income of -$27.5M is lower than NovaBay Pharmaceuticals's net income of $7.7M. Notably, Aura Biosciences's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Aura Biosciences is -- versus 0.16x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Oragenics has a net margin of -- compared to Aura Biosciences's net margin of --. Aura Biosciences's return on equity of -- beat Oragenics's return on equity of --.

Aura Biosciences has a consensus price target of $21.50, signalling upside risk potential of 235.94%. On the other hand Oragenics has an analysts' consensus of $1.00 which suggests that it could grow by 2012.89%. Given that Oragenics has higher upside potential than Aura Biosciences, analysts believe Oragenics is more attractive than Aura Biosciences.

Aura Biosciences has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Oragenics has a beta of 0.946, suggesting its less volatile than the S&P 500 by 5.446%.

Aura Biosciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Aura Biosciences pays -- of its earnings as a dividend. Oragenics pays out -- of its earnings as a dividend.

Aura Biosciences quarterly revenues are --, which are smaller than Oragenics quarterly revenues of --. Aura Biosciences's net income of -$27.5M is lower than Oragenics's net income of -$2.2M. Notably, Aura Biosciences's price-to-earnings ratio is -- while Oragenics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Aura Biosciences is -- versus 0.45x for Oragenics. Usually stocks with elevated PS ratios are considered overvalued.

Protara Therapeutics has a net margin of -- compared to Aura Biosciences's net margin of --. Aura Biosciences's return on equity of -- beat Protara Therapeutics's return on equity of --.

Aura Biosciences has a consensus price target of $21.50, signalling upside risk potential of 235.94%. On the other hand Protara Therapeutics has an analysts' consensus of $22.17 which suggests that it could grow by 626.78%. Given that Protara Therapeutics has higher upside potential than Aura Biosciences, analysts believe Protara Therapeutics is more attractive than Aura Biosciences.

Aura Biosciences has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Protara Therapeutics has a beta of 1.350, suggesting its more volatile than the S&P 500 by 34.998%.

Aura Biosciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Protara Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Aura Biosciences pays -- of its earnings as a dividend. Protara Therapeutics pays out -- of its earnings as a dividend.

Aura Biosciences quarterly revenues are --, which are smaller than Protara Therapeutics quarterly revenues of --. Aura Biosciences's net income of -$27.5M is lower than Protara Therapeutics's net income of -$11.9M. Notably, Aura Biosciences's price-to-earnings ratio is -- while Protara Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Aura Biosciences is -- versus -- for Protara Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Theriva Biologics has a net margin of -- compared to Aura Biosciences's net margin of --. Aura Biosciences's return on equity of -- beat Theriva Biologics's return on equity of --.

Aura Biosciences has a consensus price target of $21.50, signalling upside risk potential of 235.94%. On the other hand Theriva Biologics has an analysts' consensus of $7.00 which suggests that it could grow by 1294.42%. Given that Theriva Biologics has higher upside potential than Aura Biosciences, analysts believe Theriva Biologics is more attractive than Aura Biosciences.

Aura Biosciences has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Theriva Biologics has a beta of 0.816, suggesting its less volatile than the S&P 500 by 18.373%.

Aura Biosciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Aura Biosciences pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.

Aura Biosciences quarterly revenues are --, which are smaller than Theriva Biologics quarterly revenues of --. Aura Biosciences's net income of -$27.5M is lower than Theriva Biologics's net income of -$4.3M. Notably, Aura Biosciences's price-to-earnings ratio is -- while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Aura Biosciences is -- versus 0.33x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.